However, the use of TPO-RA during pregnancy (notably for delivery preparation or in case of refractory ITP) has been reported in a short retrospective series of 15 patients (17 pregnancies) that showed a response in 77% of cases without complications among mothers and neonates excepted for one transient neonatal thrombocytosis [56]. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.